Les femmes à l'épreuve du VIH - HAL

134615-PAO- Folio : p45 - Type : pINT 11-01-27 07:56:07L : 179.991 - H : 249.992 - Couleur : BlackLes spécificités épidémiologiques et cliniques de l’atteinte des femmes par le VIH15. Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusiontransmittedinfections in sub-Saharan Africa. Transfusion 2010 ; 50 : 433-42.16. Auvert B, Buvé A, Ferry B, et al. Ecological and individual level analysis on risk factorsfor HIV infection in four urban populations in sub-Saharan Africa with different levelsof HIV infection. AIDS 2001 ; 15 : S15-S30.17. WHO. Women and health. Today’s evidence tomorrow’s agenda. 2009, 108 p.18. OMS, ONUSIDA. Vers un accès universel. Étendre les interventions prioritaires liéesau VIH/sida dans le secteur de la santé. Rapport de situation, 2008.19. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortalityand nondeath losses from an antiretroviral treatment service in South Africa : implicationsfor program evaluation. Clin Infect Dis 2006 ; 43 : 770-6.20. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in10,000 adults in Côte d’Ivoire : 2-year outcomes and determinants. AIDS 2008 ; 22 :873-82.21. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseasesand HIV infection : implications for the control of both epidemics in Africa. AIDS 1991 ;5 (suppl 1) : S55-63.22. Van de Wijgert JH, Morrison CS, Cornelisse PG, et al. Bacterial vaginosis and vaginalyeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J AcquirImmune Defic Syndr 2008 ; 48 : 203-10.23. Sokal D, Karim Q, Omar Z, et al. Safety of 1 % tenofovir vaginal microbicide gel inSouth African women : results of the CAPRISA 004 trial. AIDS Conference, Vienne,Autriche, 18-23 juillet 2010. Résumé TUSS0503.24. de Vincenzi I, Mertens T. Male circumcision : a role in HIV prevention ? AIDS 1994 ;8 : 153-60.25. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized,controlled intervention trial of male circumcision for reduction of HIV infectionrisk : the Anrs 1265 Trial. PLoS Med 2005 ; 2 : e298.26. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in menin Rakai, Uganda : a randomised trial. Lancet 2007 ; 369 : 657-66.27. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in youngmen in Kisumu, Kenya : a randomised controlled trial. Lancet 2007 ; 369 : 643-56.28. Butler D, Odling-Smee L. Circumcision for HIV needs follow-up. Nature 2007 ; 447 :1040-1.29. Attia S, Egger M, Müller M, Zwahlen, Low N. Sexual transmission of HIV accordingto viral load and antiretroviral therapy : systematic review and meta-analysis. AIDS2010 ; 23 : 1397-404.30. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIVtesting with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009 ; 373 : 48-57.31. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by usinga “Test and treat” strategy ? AIDS 2010 ; 24 : 775-6.32. WHO. Antiretroviral therapy for HIV infection in infants and children : towards universalaccess. Recommendations for a public health approach. 2010 revision.Genève, Suisse, 206 pages.33. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 womenand men infected through injecting drug use and heterosexual sex and followed for13